News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Jounce Therapeutics
NEWS
JOBS
IN THE PRESS
NEWS
Juno Therapeutics was acquired by Bristol-Myers Squibb in 2019.
Deals
Cambridge-Based Jounce Files for $75 Million IPO
December 30, 2016
·
2 min read
Business
Cambridge Startup Jounce Lands $2.5 Billion Deal With Biotech’s Best Friend Celgene
July 19, 2016
·
2 min read
Drug Development
EXCLUSIVE: Jounce CEO Says Funding Aims for Trials Next Year, Will Hire 10
April 24, 2015
·
3 min read
Genetown
Jounce Infused With $56 Million to Develop Cancer Immunotherapy Programs
April 23, 2015
·
2 min read
AWARDS
JOBS
Currently, there are no jobs for this company on BioSpace
Browse all jobs
here
Oops!
There was an issue retrieving the jobs list. Please reload the page to view more jobs.
Title
Location
Company Name
Desc
View details
IN THE PRESS
Drug Development
Jounce Therapeutics Announces Results from Pre-Planned Data Review of INNATE Phase 2 Trial of JTX-8064 and Pimivalimab Demonstrating Deep and Durable Responses in Platinum Resistant Ovarian Cancer
March 16, 2023
·
6 min read
Deals
Redx and Jounce Announce Recommended Business Combination
February 23, 2023
·
19 min read
Business
Jounce Therapeutics Announces Restructuring - February 22, 2023
February 22, 2023
·
4 min read
Deals
Gilead to Acquire All Remaining Rights to Potential First-in-Class Immunotherapy GS-1811 From Jounce Therapeutics
December 27, 2022
·
7 min read
Genetown
Jounce Therapeutics Presents INNATE Phase 1 and SELECT Clinical Trial data at the European Society of Medical Oncology Immuno-Oncology (ESMO - IO) Annual Congress
December 8, 2022
·
10 min read
Business
Jounce Therapeutics Reports Third Quarter 2022 Financial Results
November 10, 2022
·
13 min read
Business
Jounce Therapeutics earns clinical milestone payment under the CCR8 exclusive license agreement with Gilead Sciences, Inc.
November 2, 2022
·
4 min read
Business
Jounce Therapeutics to Announce Third Quarter 2022 Financial Results and Host Conference Call on Thursday, November 10, 2022
October 27, 2022
·
2 min read
Genetown
Jounce Therapeutics to Present Multiple Posters at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting and the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) Annual Congress
October 20, 2022
·
6 min read
Genetown
Jounce Therapeutics to Participate in the Upcoming September 2022 Investor Conferences
September 7, 2022
·
2 min read
